Icon

TESLAC (nda016118)- (50MG,250MG)

TESTOLACTONE BRISTOL MYERS SQUIBB
50MG,250MG
No No
Expired Expired
None None
None No
TESLAC (testolactone tablets, USP) is recommended as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer in postmenopausal women when hormonal therapy is indicated.
0 0 0
Total Other Developers None
Drugs with Suitability No
50MG ** ** - - -
250MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.